Galmed Pharmaceuticals

Next Generation of Metabolic and Inflammatory Therapeutics

Health Tech & Life Sciences
Public on NASDAQ on Mar 2014

Company Overview

Snapshot

Founded in January 2000, Galmed Pharmaceuticals operates with 1–10 employees. The company has raised a total of $150.3 million across 5 funding rounds. In June 2026, Galmed Pharmaceuticals acquired Colospan to create a GI-focused platform.

Business overview

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases. Its core product, Aramchol, is a drug candidate currently undergoing a Phase 3 registrational study for the treatment of NASH and fibrosis. The company also collaborates with the Hebrew University on the development of Amilo-5MER, a 5 amino acid synthetic peptide, and is expanding its activities into cancer and major cardiometabolic diseases. Galmed Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In May 2026, Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics. This partnership signals a strategic expansion of Aramchol's potential applications beyond liver diseases, indicating a broader therapeutic focus and potential market opportunities for investors in the cardiometabolic disease space.

Company Intelligence Q&A

What was a significant recent development for Galmed Pharmaceuticals regarding its lead compound?
In May 2026, Galmed Pharmaceuticals announced results from a first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine (AM), demonstrating that 400mg AM increases bioavailability by approximately 500% compared to Aramchol Free Acid (AA) 300mg.
What strategic acquisition did Galmed Pharmaceuticals complete recently?
In June 2026, Galmed Pharmaceuticals acquired Colospan to establish a GI-focused platform, targeting a market valued at $6 billion.
What new patent was allowed for Aramchol in September 2023?
In September 2023, a new patent was allowed for Aramchol for the treatment of pulmonary and dermal fibrosis, expanding its potential therapeutic applications.
What expansion of activities did Galmed Pharmaceuticals announce in September 2024?
In September 2024, Galmed Pharmaceuticals announced an expansion of its activities into cancer and major cardiometabolic diseases, broadening its research and development focus.
What were the key findings from Aramchol's oncology studies announced in November 2025?
In November 2025, Galmed announced top-line results from oncology studies showing that a three-drug combination of Aramchol, Stivarga®, and Metformin significantly enhanced GI tumor cell killing in vivo and in vitro.

External links